Search Result

20332

Results Found

Relevance

Filter

Newest

Filter

Most Viewed

Filter

Most Downloaded

Filter

Most Cited

Filter

Pages Count

2034

Go To Page

Search Results/Filters    

Filters

Year

Banks



Expert Group











Full-Text


مرکز اطلاعات علمی SID1
اسکوپوس
دانشگاه غیر انتفاعی مهر اروند
ریسرچگیت
strs
Author(s): 

DIENSAG J.L.

Issue Info: 
  • Year: 

    2011
  • Volume: 

    306
  • Issue: 

    -
  • Pages: 

    0-0
Measures: 
  • Citations: 

    473
  • Views: 

    23937
  • Downloads: 

    31595
Keywords: 
Abstract: 

Yearly Impact:

View 23937

Download 31595 Citation 473 Refrence 0
Author(s): 

HAGHAZALI S.

Journal: 

GOVARESH JOURNAL

Issue Info: 
  • Year: 

    2002
  • Volume: 

    7
  • Issue: 

    37-38
  • Pages: 

    45-49
Measures: 
  • Citations: 

    0
  • Views: 

    2170
  • Downloads: 

    133
Keywords: 
Abstract: 

Autoimmune HEPATITIS (AIH) is one of causes of CHRONIC liver diseases. It is an unresolving inflammation of liver tissue and characterized by elevated transaminases, hypergammaglobulinemia, and circulating autoantibodies. The disorder occurs mostly in females (F:M ratio is 3.6 to 1) and is a relatively uncommon disorder with point prevalence of 8-16.8 per 100 000 population in western countries. Hiostologic hallmarks are interface HEPATITIS (also called piecemeal necrosis), and portallymphoplasmacytic infiltration.Dignostic criteria are based on excluding other etiologies of CHRONIC liver disease,such as viral hepatic (A, B, C), metabolic disorders eg Wilson disese,drug induced HEPATITIS and alcoholic liver disease. Conventional autoantibodies are Antinuclear antibody (ANA), Smooth muscle antibody (SMA) and Anti liver kidney microsomal 1 (Anti LKM1).Some cases have combined clinical, laboratory or histologic features of Primary Biliary Cirrhosis (PBC) or Primary Sclerosing Cholangitis (PSC) with AIH and are known as overlap syndrome. Standard treatments of AIH as the most successful treated form of CHRONIC HEPATITIS are based on immunosuppression with corticosteroids alone or in combination with azathioprine.

Yearly Impact:

View 2170

Download 133 Citation 0 Refrence 1
Author(s): 

LOK A.S. | MCMAHON B.J.

Journal: 

HEPATOLOGY

Issue Info: 
  • Year: 

    2007
  • Volume: 

    45
  • Issue: 

    2
  • Pages: 

    507-539
Measures: 
  • Citations: 

    466
  • Views: 

    18211
  • Downloads: 

    30113
Keywords: 
Abstract: 

Yearly Impact:

View 18211

Download 30113 Citation 466 Refrence 0
گارگاه ها آموزشی
Issue Info: 
  • Year: 

    2007
  • Volume: 

    50
  • Issue: 

    96
  • Pages: 

    217-229
Measures: 
  • Citations: 

    0
  • Views: 

    1096
  • Downloads: 

    2188
Keywords: 
Abstract: 

Introduction: CHRONIC HEPATITIS B is a major medical problem, distributing all over the world. Affecting more than 400 million people. In highly prevalence places, childhood transmission is the most common form but in low prevalence areas, injection, drug use and familial transmission are the main routes of acquisation of infection. Hepatocellular carcinoma and cirrhosis are significant problems of CHRONIC HEPATITIS B. Exposure to HBV early in life may progress to hepatocellar carcinoma. The annual number of deaths from HBV infection and related diseases throughout the world is about 1.2 million. The goal of treatment of CHRONIC HEPATITIS B with Lamivudin or INF-Alpha is sustained suppression of virus replication and liver disease remission. INF, Alpha and Lamivudin have similiar efficacy. The adventage of Lamivudin is that it is less expensive and is well tolerated and adventages of INF. Alpha are the short duration of treatment and absence of resistance but it is expensive and has many side effects. The response rate of INF. Alpha is better than Lamivudin but it is associated with a large number of side effects, sometimes we have to stop or decrease the dose of INF. Viral genotypes and other factors such as pretreatment viral load, fatty liver and liver histiology may alter the response rate. The long-term use of Lamivudin may be with the emergence of YMDD mutations. Treatment of YMDD form of chromic HEPATITIS B, with combination of Lamivudin and Adefovir dipivoxil, may improve liver function; and YMDD mutations may be over come. The emergence of YMDD mutations reduces the benefit of Lamivudin but does not negate it.

Yearly Impact:

View 1096

Download 2188 Citation 0 Refrence 3
Author(s): 

LOCK A.S. | MCMAHAN B.J.

Journal: 

HEPATOLOGY

Issue Info: 
  • Year: 

    2007
  • Volume: 

    45
  • Issue: 

    2
  • Pages: 

    507-539
Measures: 
  • Citations: 

    1425
  • Views: 

    32250
  • Downloads: 

    31995
Keywords: 
Abstract: 

Yearly Impact:

View 32250

Download 31995 Citation 1425 Refrence 0
Journal: 

HEPATOLOGY

Issue Info: 
  • Year: 

    2001
  • Volume: 

    34
  • Issue: 

    4
  • Pages: 

    617-624
Measures: 
  • Citations: 

    457
  • Views: 

    12528
  • Downloads: 

    28498
Keywords: 
Abstract: 

Yearly Impact:

View 12528

Download 28498 Citation 457 Refrence 0
strs
Author(s): 

VAEZ JALALI M. | ALAVIAN S.M.

Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2006
  • Volume: 

    6
  • Issue: 

    1
  • Pages: 

    31-35
Measures: 
  • Citations: 

    0
  • Views: 

    111276
  • Downloads: 

    75089
Keywords: 
Abstract: 

IntroductionHEPATITIS B virus (HBV) infection is a global health problem. Current estimates are that 2 billion people have been infected worldwide, of these, 360 million suffer from CHRONIC HBV infection resulting in over 520 000 deaths from acute HEPATITIS B and 470 000 from cirrhosis or liver cancer(1). The prevalence of HEPATITIS B carriers varies in different parts of the world, ranging from less than 1% to 15%. In the Middle East, the endemicity is intermittent, with a carrier rate of 2% to 7% (2). It is estimated that over 35% of Iranians have been exposed to the HBV and about 3% are CHRONIC carriers, ranging from 1.7% in Fars Province to over 5% in Sistan and Balouchestan(3).

Yearly Impact:

View 111276

Download 75089 Citation 0 Refrence 0
Author(s): 

SOLEIMAN MEIGOUNI SAEED | ASGARI ALI | HOSSEINI SHOKOUH SEYED JAVAD | RAJABI JALIL | KAZEMI GALOUGAHI MOHAMMAD HASSAN | MOSHTAGHI MOHAMMAD

Journal: 

ELECTRONIC PHYSICIAN

Issue Info: 
  • Year: 

    2015
  • Volume: 

    7
  • Issue: 

    1
  • Pages: 

    985-989
Measures: 
  • Citations: 

    0
  • Views: 

    79957
  • Downloads: 

    30181
Abstract: 

Background: HEPATITIS G virus (HGV) is a hepatotrope virus with unknown importance. The genome of the virus has been detected in patients with acute or CHRONIC non-A-E HEPATITIS, cirrhosis, and hepatocellular carcinoma. The aim of this study was to determine the association between HEPATITIS G and unknown CHRONIC HEPATITIS.Methods: This case-control study was performed in Ebne-Sina military hospital in Hamadan, Iran. The cases were 35 military staff with unknown CHRONIC HEPATITIS. The control group consisted of 59 healthy subjects who had normal levels of serum alanine aminoteransferase (ALT). The data were analyzed by SPSS, version18, using Fisher’s exact test, the Student’s t-test, and multivariate logistic regression analysis.Results: Only one patient in the case group (2.9%) tested positive for HGV antibodies, and no one was infected in the control group. There was no association between HGV infection and unknown CHRONIC HEPATITIS in our study (P=0.37). A significant association was found between the male gender and unknown CHRONIC HEPATITIS (OR=14.9, P=0.01).Conclusion: No association between HGV infection and unknown CHRONIC HEPATITIS was found in our study, so it was not necessary to evaluate these patients for HGV infection.

Yearly Impact:

View 79957

Download 30181 Citation 0 Refrence 0
Journal: 

GOVARESH JOURNAL

Issue Info: 
  • Year: 

    2003
  • Volume: 

    8
  • Issue: 

    44
  • Pages: 

    67-71
Measures: 
  • Citations: 

    0
  • Views: 

    5016
  • Downloads: 

    133
Abstract: 

Background: Advanced hepatic fibrosis and cirrhosis has generally been considered to be irreversible. The aim of this study was to determine whether cirrhosis is reversible.Methods: Seven patients with autoimmune HEPATITIS with histologic evidence of cirrhosis were enrolled. After treatment, they had follow-up liver biopsy while in clinical and biochemical remission. Biopsy specimens were randomly coded in unpaired manner according to patient and were read independently by two pathologists using the modified HEPATITIS activity index (with a maximum stage of 6).Results: Three patients still had extensive fibrosis in the second liver biopsy. But four patients had almost total regression of their liver fibrosis. In the latter patients, the mean alanine aminotransferase level decreased from 776.3 U/L to 23 U/L. The mean bilirubin level decreased from 5.85 mg/dL, to 0.98 mg/dL. Extensive fibrosis or cirrhosis were present in all patients at diagnosis but were not present on follow-up liver biopsy. The mean fibrosis score decreased from 5.88 to 0.5 (P=0.0002), and the mean grading score from 11.38 to 2.5 (P=0.0008.).Conclusion: Frank cirrhosis due to autoimmune HEPATITIS may be reversible in some patients who respond to treatment.

Yearly Impact:

View 5016

Download 133 Citation 0 Refrence 0
Author(s): 

MOHANTY S.R. | KHIANI V.

Issue Info: 
  • Year: 

    2006
  • Volume: 

    3
  • Issue: 

    -
  • Pages: 

    446-458
Measures: 
  • Citations: 

    472
  • Views: 

    13410
  • Downloads: 

    31395
Keywords: 
Abstract: 

Yearly Impact:

View 13410

Download 31395 Citation 472 Refrence 0
litScript